Published in J Clin Invest on April 01, 1986
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody. J Clin Invest (1988) 0.75
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg (1970) 12.72
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A (1971) 5.38
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med (1976) 5.05
Immunological enhancement of tumor homografts in mice: a review. Cancer Res (1958) 4.61
Analyzing data from ordered categories. N Engl J Med (1984) 4.40
Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 4.24
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med (1977) 3.42
Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A (1980) 2.14
The nature of immune complexes in human cancer sera. J Immunol (1977) 1.88
AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization. Proc Natl Acad Sci U S A (1979) 1.86
Inhibition of hepatoma-immune lymph-node cell cytotoxicity by tumour-bearer serum, and solubilized hepatoma antigen. Int J Cancer (1973) 1.49
The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med (1981) 1.45
Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst (1981) 1.30
Direct blockade of antigen-reactive B lymphocytes by immune complexes. An 'off' signal for precursors of IgM-producing cells provided by the linkage of antigen-and Fc-receptors. Immunology (1978) 1.16
Circulating immune complexes and the prognosis of acute myeloid leukemia. N Engl J Med (1982) 1.00
Identification and purification of a Mr 75,000 cell surface human melanoma-associated antigen. Cancer Res (1982) 0.95
Tumor-associated antigens in spent medium of human melanoma cells: immunochemical characterization with xenoantisera. J Immunol (1981) 0.94
Blocking factors against leucocyte-dependent melanoma antibody in the sera of melanoma patients. Br J Cancer (1977) 0.88
Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum. Cancer Res (1984) 0.86
Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical Stage I. Cancer (1985) 0.84
Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients. Cancer Res (1983) 0.84
Beneficial and detrimental effects of humoral immunity in malignancy. Pathobiol Annu (1978) 0.82
Tumor induced immunosuppression. Surg Gynecol Obstet (1983) 0.82
Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes. J Clin Invest (1985) 0.80
Prognostic significance of leukocyte-dependent antibody activity in melanoma patients. J Natl Cancer Inst (1983) 0.77
Evaluation of assays to detect immune complexes as an immunodiagnostic aid in patients with melanoma. Oncodev Biol Med (1982) 0.77
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Reporting on methods in clinical trials. N Engl J Med (1982) 3.98
Trial of calcium to prevent preeclampsia. N Engl J Med (1997) 3.69
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65
Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA (1999) 2.34
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19
Serum cotinine concentration and self-reported smoking during pregnancy. Am J Epidemiol (1998) 2.15
Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res (1991) 1.73
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51
Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol (2002) 1.43
Human melanocytes cultured from nevi and melanomas. J Invest Dermatol (1986) 1.36
Deaths attributable to injuries in infants, United States, 1983-1991. Pediatrics (1999) 1.34
Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am (1984) 1.30
Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. N Engl J Med (1999) 1.29
SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene (2007) 1.29
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res (2000) 1.26
Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods (1992) 1.22
Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys (1998) 1.22
Interferons in the treatment of human cancer. J Clin Oncol (1984) 1.22
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A (2000) 1.19
Epidural analgesia in association with duration of labor and mode of delivery: a quantitative review. Am J Obstet Gynecol (1999) 1.17
Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol (2001) 1.14
Corticosteroid treatment for idiopathic facial nerve paralysis: a meta-analysis. Laryngoscope (2000) 1.14
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist (2000) 1.09
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol (1997) 1.08
Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods. Control Clin Trials (1996) 1.07
Interpretation of linear regression models that include transformations or interaction terms. Ann Epidemiol (1992) 1.03
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer (2001) 1.02
Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest (2000) 1.02
Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res (1996) 1.01
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med (1985) 0.98
Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. Endocrinology (1984) 0.94
Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun (1984) 0.94
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res (1985) 0.94
Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol (2001) 0.94
An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol (1992) 0.93
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol (1993) 0.93
Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial. Cancer Res (1980) 0.92
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol (2012) 0.92
A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (1990) 0.92
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer (1999) 0.91
Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma. Mol Med (1999) 0.90
Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry (1996) 0.90
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol (1997) 0.89
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res (1996) 0.89
Molecular analysis of melanoma precursor lesions. Cell Growth Differ (1996) 0.89
Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res (2001) 0.89
Interferons in melanoma. Curr Opin Oncol (1996) 0.88
New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res (1996) 0.88
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol (1984) 0.88
IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther (2006) 0.87
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol (1987) 0.87
Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum. Cancer Res (1984) 0.86
Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep (1984) 0.86
Combining evidence from clinical trials. Anesth Analg (1990) 0.86
Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med (1988) 0.85
Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer (2000) 0.85
Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol (2000) 0.84
Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg (1993) 0.84
Dysplastic nevi in association with multiple primary melanoma. Cancer Res (1988) 0.83
Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev (1984) 0.83
Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol (1986) 0.83
A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol (1987) 0.83
Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer (2011) 0.82
Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI. Br J Cancer (1991) 0.82
Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res (2000) 0.82
Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute. Melanoma Res (1993) 0.81
A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. Epidemiology (1991) 0.81
Changes in Connecticut hospital use rates: have small-area variations been affected? Inquiry (1990) 0.80
Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes. J Clin Invest (1985) 0.80
Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol (1994) 0.80
Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res (1992) 0.80
Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res (1996) 0.80
Effects of oral contraceptives and pregnancy on melanomas. N Engl J Med (1979) 0.80
Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther (2000) 0.80
Analysis of two human monoclonal antibodies against melanoma. Int J Cancer (1992) 0.79
Predicting asthma severity from allergic sensitivity to cockroaches in pregnant inner city women. J Reprod Med (2000) 0.79
Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma. Clin Exp Immunol (1991) 0.79
Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med (1984) 0.79
Conference on meta-analysis in the design and monitoring of clinical trials. Stat Med (1999) 0.79
Adjuvant therapy of melanoma. Semin Surg Oncol (1998) 0.79
Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol (1996) 0.79
Melanoma: therapeutic options with recombinant interferons. Semin Oncol (1985) 0.78
Comparison of nonfamilial and familial melanoma. Dermatology (1992) 0.78